Introduction Cost-effectiveness analyses are becoming increasingly important in Japan following the introduction of a health technology assessment scheme. The study objective was to develop an economic model to evaluate the cost-effectiveness of two interventions for type 2 diabetes in a Japanese population. Research design and methods The Japan Diabetes Complications Study/Japanese Elderly Diabetes Intervention Trial risk engine (JJRE) Cost-Effectiveness Model (JJCEM) was developed, incorporating validated risk equations in Japanese patients with type 2 diabetes from the JJRE. Weibull regression models were developed for progression of the model outcomes, and a targeted literature review was performed to inform default values for utilities and costs. To illustrate outcomes, two simulated analyses were performed in younger (aged 40 years) and older (aged 80 years) Japanese populations, comparing a hypothetical treatment with placebo. Results The model considers a population based on user-defined values for 11 baseline characteristic parameters and simulates rates of diabetic complications over a defined time horizon. Costs, quality-adjusted life years, and an incremental cost-effectiveness ratio are estimated. The model provides disaggregated results for two competing interventions, allowing visualization of the key drivers of cost and utility. A scatterplot of simulations and cost-effectiveness acceptability curve are generated for each analysis. Conclusions This is the first cost-effectiveness model for East Asian patients with type 2 diabetes, developed using Japan-specific risk equations. This population constitutes the largest share of the global population with diabetes, making this model highly relevant. The model can be used to evaluate the cost-effectiveness of anti-diabetic interventions in patients with type 2 diabetes in Japan and other East Asian populations. Data sharing not applicable as no datasets generated and/or analyzed for this study.

中文翻译：

---

基于日本糖尿病并发症研究和日本老年糖尿病干预试验为亚洲 2 型糖尿病患者开发健康经济模型

介绍 随着卫生技术评估计划的引入，成本效益分析在日本变得越来越重要。该研究的目标是开发一种经济模型来评估日本人群中两种干预措施对 2 型糖尿病的成本效益。研究设计和方法 开发了日本糖尿病并发症研究/日本老年糖尿病干预试验风险引擎 (JJRE) 成本效益模型 (JJCEM)，其中纳入了 JJRE 在日本 2 型糖尿病患者中验证的风险方程。为模型结果的进展开发了威布尔回归模型，并进行了有针对性的文献审查，以告知公用事业和成本的默认值。为了说明结果，在较年轻（40 岁）和年长（80 岁）日本人群中进行了两项模拟分析，将假设治疗与安慰剂进行比较。结果 该模型考虑了基于用户定义的 11 个基线特征参数值的群体，并在定义的时间范围内模拟糖尿病并发症的发生率。估计成本、质量调整寿命年和增量成本效益比。该模型为两种相互竞争的干预措施提供了分解结果，允许成本和效用的关键驱动因素可视化。每次分析都会生成模拟散点图和成本效益可接受性曲线。结论 这是第一个使用日本特定风险方程开发的东亚 2 型糖尿病患者的成本效益模型。该人群占全球糖尿病人群的最大份额，使该模型高度相关。该模型可用于评估日本和其他东亚人群 2 型糖尿病患者抗糖尿病干预措施的成本效益。数据共享不适用，因为没有为本研究生成和/或分析的数据集。